Industry updates from the field of stem cell research and regenerative medicine in April 2023
Abstract
Latest developments in the field of stem cell research and regenerative medicine compiled from publicly available information and press releases from non-academic institutions in April 2023.
Tweetable abstract
Regenerative medicine industry news digest, April 2023.
References
- 1. Grünenthal. Grünenthal and King's College London collaborate to develop human induced pluripotent stem cell-based microfluidic cultures for pain research (2023). www.grunenthal.com/en/press-room/press-releases/2023/pr-grunenthal-and-kings-college-london-announce-collaboration
- 2. LyGenesis. LyGenesis and Imagine Pharma Announce Joint Research Collaboration to Develop Novel Cell Therapies for Patients with Type 1 Diabetes (2023). www.lygenesis.com/media/press-releases/lygenesis-and-imagine-pharma-announce-joint-research-collaboration-to-develop-novel-cell-therapies-for-patients-with-type-1-diabetes
- 3. ImaginAb. ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with Leucid Bio (2023). https://imaginab.com/news-events/news/imaginab-execuites-new-license-and-supply-agreement-for-cd8-immunopet-technology-with-leucid-bio/
- 4. Precigen. Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T® (2023). https://investors.precigen.com/node/13176/pdf
- 5. PR Newswire. Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University (2023). www.prnewswire.com/news-releases/theralink-acquires-exclusive-landmark-immunotherapy-patent-including-biomarker-from-vanderbilt-university-301787847.html
- 6. Novo Nordisk. Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity (2023). www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166089
- 7. Gingko Bioworks. Ginkgo Bioworks and WARF Announce Partnership to Discover Next Generation GD2 CAR T-Cell Therapies (2023). https://investors.ginkgobioworks.com/news/news-details/2023/Ginkgo-Bioworks-and-WARF-Announce-Partnership-to-Discover-Next-Generation-GD2-CAR-T-Cell-Therapies/default.aspx
- 8. eGenesis. Karius and eGenesis partner to help accelerate xenotransplantation for patients in need of organ transplants (2023). https://egenesisbio.com/press-releases/karius-and-egenesis-partner-to-help-accelerate-xenotransplantation-for-patients-in-need-of-organ-transplants/
- 9. Astellas Pharma. CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells (2023). www.astellas.com/en/system/files/news/2023-04/20230412_en_1.pdf
- 10. OBiO Technology. OBiO and CHINAGENE reached a strategic agreement of commercial manufacturing services for gene therapy products (2023). www.obio-tech.com/cn/home/news/id/217
- 11. BioLineRx. BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating Motixafortide and G-CSF in Stem Cell Mobilization for Autologous Transplantation in Multiple Myeloma (2023). https://ir.biolinerx.com/node/13271/pdf
- 12. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial. Nat. Med. 29, 869–879 (2023).
- 13. NCT03246529. A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS with MM (GENESIS) (2022). https://clinicaltrials.gov/ct2/show/NCT03246529
- 14. CTRL Therapeutics. CTRL Therapeutics Launches with $10 M Seed Financing to Advance Next-Generation Cell Therapy Platform for the Treatment of Solid Tumors (2023). www.ctrl-therapeutics.com/press-release
- 15. Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting. Nat. Biomed. Eng.
doi: 10.1038/s41551-023-01023-3 (2023). - 16. PR Newswire. LifeNet Health LifeSciences launches TruVivo™, a pioneering all-human 2D+ hepatic system, to revolutionize compound discovery (2023). www.prnewswire.com/news-releases/lifenet-health-lifesciences-launches-truvivo-a-pioneering-all-human-2d-hepatic-system-to-revolutionize-compound-discovery-301788815.html16
- 17. OBiO Technology. A new super factory with 29 GMP grade production lines for gene and cell therapy was launched in Shanghai by OBiO technology (2023). www.obio-tech.com/cn/home/news/id/216
- 18. Synthego. Synthego Launches Express Cell Pools for Faster, More Efficient Genome Editing (2023). www.synthego.com/press/synthego-launches-express-cell-pools
- 19. Bristol Myers Squibb. Regulatory Applications Accepted Across Three Regions Globally for Abecma for Earlier Use in Adults with Triple-Class Exposed Relapsed and/or Refractory Multiple Myeloma (2023). https://news.bms.com/news/corporate-financial/2023/Regulatory-Applications-Accepted-Across-Three-Regions-Globally-for-Abecma-for-Earlier-Use-in-Adults-with-Triple-Class-Exposed-Relapsed-andor-Refractory-Multiple-Myeloma/default.aspx
- 20. NCT03651128. Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3) (2022). https://clinicaltrials.gov/ct2/show/NCT03651128
- 21. Caribou Biosciences. Caribou Biosciences Announces FDA Granted Fast Track Designation to CB-011, an Allogeneic CAR-T Cell Therapy for Relapsed or Refractory Multiple Myeloma (2023). https://investor.cariboubio.com/node/7946/pdf
- 22. NCT05722418. CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CaMMouflage). https://clinicaltrials.gov/ct2/show/NCT05722418
- 23. CARsgen Therapeutics. CARsgen's CAR T-cell Candidate CT041 Achieves IND Clearance from the NMPA for the Postoperative Adjuvant Therapy of Pancreatic Cancer (2023). http://www.carsgen.com/en/news/20230420/
- 24. Editas Medicine. Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease (2023). https://ir.editasmedicine.com/node/11566/pdf
- 25. Gamida Cell. Gamida Cell's Allogeneic Cell Therapy Omisirge® (omidubicel-onlv) Receives FDA Approval (2023). https://investors.gamida-cell.com/node/9426/pdf
- 26. JW Therapeutics. JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus (2023). www.jwtherapeutics.com/en/media/press-release/jw-therapeutics-announces-ind-approval-for-the-clinical-trial-of-carteyva-in-patients-with-moderately-or-severely-refractory-systemic-lupus-erythematosus/
- 27. REGENXBIO. REGENXBIO Receives FDA Fast Track Designation for RGX-202, a Novel Gene Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy (2023). https://regenxbio.gcs-web.com/node/11376/pdf
- 28. PR Newswire. Verismo Therapeutics Secures Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110 (2023). www.prnewswire.com/news-releases/verismo-therapeutics-secures-fast-track-designation-from-the-us-food-and-drug-administration-fda-for-synkir-110-301789884.html
- 29. NCT05568680. SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (2023). https://clinicaltrials.gov/ct2/show/NCT05568680
- 30. XNK Therapeutics. XNK Receives EU Tissue Establishment Certificate (2023). https://xnktherapeutics.com/en/xnk-receives-eu-tissue-establishment-certificate/
- 31. Businesswire. Ossium Health Awarded $3.46 M in Funding from the California Institute of Regenerative Medicine (CIRM) to Advance the Development of OSSM-007 for the Treatment of Steroid-Refractory Acute Graft versus Host Disease (GVHD) (2023). www.businesswire.com/news/home/20230428005039/en